Miracle Leaf® qualifying-conditions guide

Medical Marijuana for Spinal Cord Injury

Damage to the spinal cord resulting in temporary or permanent changes in motor, sensory, or autonomic function. Cannabis has moderate evidence for reducing spasticity and managing neuropathic pain in spinal cord injury patients.

Reviewed by Miracle Leaf® Editorial Team

Last reviewed 2026-08-04

Book Evaluation Call (833) LEGAL-MJ

NASEM evidence levelModerateICD-10: T09.3XXA

What is Spinal Cord Injury?

Spinal cord injury (SCI) results from damage to the spinal cord by trauma, disease, or congenital condition, producing temporary or permanent changes in motor, sensory, and autonomic function below the level of injury. Severity and functional impact depend on injury level and completeness. Common chronic complications include spasticity, neuropathic pain, autonomic dysreflexia, and bladder/bowel dysfunction.

Does cannabis help Spinal Cord Injury?

The 2017 NASEM consensus report identified substantial evidence that oral cannabinoids improve patient-reported spasticity symptoms. A finding that applies to MS spasticity and is generally extended to other causes of central spasticity including spinal cord injury.

Evidence for neuropathic pain control following SCI is more variable but has been reported as a primary benefit by patients in survey and clinical studies. Spinal cord injury is not a qualifying condition under Florida OMMU, Georgia DPH, or Texas TCUP (Occupations Code §169.003). Patients whose SCI involves a co-occurring condition that is listed, such as spasticity, chronic pain, or an incurable neurodegenerative disease, should discuss eligibility under that listed condition with a state-registered physician.

Eligibility

State eligibility for Spinal Cord Injury

Whether this condition is listed varies by state program. A Miracle Leaf® physician determines eligibility during your evaluation.

State-by-state eligibility for Spinal Cord Injury: whether the condition qualifies under Florida, Georgia, and Texas medical cannabis programs.
State	Qualifies?	Program
Florida	Not listed	Florida OMMU
Georgia	Not listed	Georgia DPH Medical Cannabis Registry
Texas	Not listed	Texas Compassionate Use Program

This table covers Florida, Georgia, and Texas, the three states where Miracle Leaf® operates clinics. Miracle Leaf® also serves patients by telehealth in 22 more states, where qualifying conditions are set by each state's own program. See the telehealth state guides for eligibility where you live.

Outside Florida, Georgia, or Texas?

Telehealth visits are available in 22 states. See telehealth states

Common questions

Frequently asked questions

How strong is the cannabis evidence for spinal cord injury?

Moderate for spasticity and neuropathic pain (the two most common chronic complications of SCI). The 2017 NASEM report identified substantial evidence that oral cannabinoids are effective for improving patient-reported spasticity symptoms, and substantial evidence for chronic pain in adults. SCI-specific trials are smaller than MS trials but consistent in direction.

Is any cannabis-derived product FDA-approved for SCI?

No. No cannabis or cannabinoid product is FDA-approved specifically for spinal cord injury in the United States. Nabiximols (Sativex), an oromucosal THC/CBD spray, is approved in many other countries for MS-related spasticity and is sometimes referenced in SCI literature; it is not FDA-approved in the US.

Spasticity and neuropathic pain have the most consistent evidence. Sleep disturbance, appetite, and bladder spasticity are also commonly cited in patient surveys; trial evidence in these domains is more limited. Cannabis is most commonly used as adjunctive therapy alongside standard SCI management (baclofen, gabapentinoids, antispasmodics).

What practical considerations apply when SCI patients use cannabis?

Cannabis can interact with baclofen, gabapentin, opioids, and antispasmodics through additive CNS depression. Smoking is contraindicated in patients with respiratory compromise (high cervical injuries). Edibles, oils, and tinctures are generally preferred. Patients should coordinate cannabis use with their physiatry, pain-management, and primary-care teams.

Sources and citations

NASEM: The Health Effects of Cannabis and Cannabinoids (2017)
“Substantial evidence that oral cannabinoids are effective for improving patient-reported spasticity symptoms.”
NIH National Institute of Neurological Disorders and Stroke: Spinal Cord Injury

Ready to talk with a Miracle Leaf® physician?

Book Evaluation Call (833) LEGAL-MJ Shop Now

Reviewed by Miracle Leaf® Editorial Team. This page summarizes current peer-reviewed evidence and federal guidance and is updated when the source documents materially change.